Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive
and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes
(CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to
Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be
randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary
objectives are to assess the effect of AGB101 compared with placebo on clinical progression
as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire
(FAQ).